Title: The lost microbes of COVID-19: Bifidobacterium, Faecalibacterium depletion and decreased microbiome diversity associated with SARS-CoV-2 infection severity

Authors: Sabine Hazan,[*1] Neil Stollman,[2] Huseyin Bozkurt,[3] Sonya Dave,[4] Andreas J. Papoutsis,[1] Jordan Daniels,[1] Brad D. Barrows,[1] Eamonn MM Quigley,[5] Thomas J. Borody[6]

[1]ProgenaBiome, Ventura, CA, USA; [2]Division of Gastroenterology, Alta Bates Summit Medical Center, Oakland CA; [3] Istanbul Maltepe University Medicine, Clinic of Gastroenterology, Istanbul, Turkey; [4] Microbiome Research Inc., Ventura, CA, USA; [5] Lynda K and David M Underwood Center for Digestive Disorders, Houston Methodist Hospital, Houston, TX, USA; [6] Centre for Digestive Diseases, Five Dock, NSW, Australia

* Corresponding author:

Sabine Hazan, MD

ProgenaBiome, LLC

1845 Knoll Drive, Ventura, CA 93003

DrHazan@progenabiome.com

Word Count: 4,488

ABSTRACT:

Objective: The study objective was to compare gut microbiome diversity and composition in SARS-CoV-2 polymerase chain reaction (PCR)-positive patients whose symptoms ranged from asymptomatic to severe, versus PCR-negative exposed controls.

Design: Using a cross-sectional design, we performed shotgun next-generation sequencing (NGS) on stool samples to evaluate gut microbiome composition and diversity in both patients with SARS-CoV-2 PCR-confirmed infections, that had presented to Ventura Clinical Trials for care from March 2020 through October 2021, and SARS-CoV-2 PCR-negative exposed controls. Patients were classified as being asymptomatic or having mild, moderate, or severe symptoms based on NIH criteria. Exposed controls were individuals with prolonged or repeated close contact with patients with SARS-CoV-2 infection or their samples, e.g. household members of patients or frontline healthcare workers. Microbiome diversity and composition were compared between patients and exposed controls at all taxonomic levels.

Results: Compared with controls (n=20), severely symptomatic SARS-CoV-2 infected patients (n=28) had significantly less bacterial diversity (Shannon Index, P=0.0499; Simpson Index, P=0.0581), and positive patients overall had lower relative abundances of Bifidobacterium (P<0.0001), Faecalibacterium (P=0.0077), and Roseburium (P=0.0327), while having increased Bacteroides (P=0.0075). Interestingly, there was an inverse association between disease severity and abundance of the same bacteria.

Conclusion: We hypothesize that low bacterial diversity and depletion of Bifidobacterium genera either before or after infection led to reduced pro-immune function, thereby allowing SARS-CoV-2 infection to become symptomatic. This particular dysbiosis pattern may be a susceptibility marker for symptomatic severity from SARS-CoV-2 infection and may be amenable to pre-, intra-, or post infection intervention.**Keywords:** SARS-CoV-2, COVID, Microbiome, Bifidobacterium, Faecalibacterium, Bacteriodes, Shannon Index, Simpson Index, Severity, Microbiota

Registration: clinicaltrials.gov NCT04031469 (PCR -) and 04359836 (PCR+)

What is already known about this subject?	The gut microbiome is intrinsically related to host immune response (e.g., inflammation, TH1 vs. TH2) and susceptibility to infection.
What are the new findings?	Patients with SARS-CoV-2 infections possess significantly less bacterial diversity, lower abundance of *Bifidobacterium* and *Faecalibacterium,* and increased abundance of *Bacteroides* at the genus level compared with SARS-CoV-2 exposed controls. There are inverse associations between disease severity and the Shannon and Simpson diversity indices and also with *Bifidobacterium* and *Faecalibacterium* abundance. There is also a direct association between severity and *Bacteroides* abundance.
How might it impact on clinical practice in the foreseeable future?	Boosting of *Bifidobacterium* or *Faecalibacterium* through probiotic supplementation or fecal microbiota transplant is worthy of exploration in the management of patients with acute severe disease or protracted infection. If the changes that we document precede SARS-CoV-2 infection in those who are most severely affected, this therapeutic approach may be of particular interest. Conversely, if the reduction follows infection, then repopulation of the gut microbiome may reduce long-term effects related to gut microbiome composition changes with SARS-CoV-2 infection.

INTRODUCTION

The abundance of *Bifidobacterium* decreases with increasing age and BMI[1] and *Bifidobacterium* is the active ingredient of many probiotics. *In-vitro* studies have demonstrated the benefits of these Gram positive bacteria to include enhanced ATP production, immune modulation and competence,[2, 3, 4, 5, 6, 7, 8] mucosal barrier integrity, restriction of bacterial adherence to, and invasion of, the intestinal epithelium, and modulation of central nervous system activity.[9, 10] Additionally, many *Bifidobacterium spp.* have anti-inflammatory properties: *Bifidobacterium animalis, Bifidobacterium longum,* and *Bifidobacterium bifidum* decrease the function of the "master switch[2]" pro-inflammatory tumor necrosis factor- (TNF-) α, increase the anti-inflammatory cytokine interleukin- (IL-10), and promote the TH1 while inhibiting the TH2 immune response.[8] In a mouse model of inflammatory bowel disease, *B. bifidum* and *B. animalis* reduced pro-inflammatory cytokines and restored intestinal barrier integrity.[8]

With respect to SARS-CoV-2 infection, there is immunologic coordination between the gut and lungs.[11, 12, 13] Numerous studies have suggested that a healthy gut microbiome may be associated with a decrease in SARS-CoV-2 related mortality[14] and that probiotics should be considered for prophylaxis[15] and/or treatment of SARS-CoV-2 or its associated secondary infections. [15][16] [17] However, as of Feb. 2022, despite the publication of nearly 8000 studies on SARS-CoV-2 infection, few ongoing studies (clinicaltrials.gov: NCT04443075 and NCT04486482) and only 5 publications to date have examined gut microbiome changes in SARS-CoV-2 infected patients. Nevertheless, an association between the status of the gut microbiome and outcome from this infection has been suggested. Accordingly, increased abundance of the *Streptococcus, Rothia, Veilonella,* and *Actinomyces* genera was associated with inflammation, [18] whereas increased abundances of *Collinsella aerofaciens, Collinsella tanakaei, Streptococcus infantis*, and *Morganella morganii* were associated with fecal samples with high SARS-CoV-2 infectivity,[19] and increased Lachnospriaceae and Enterobacterioaceae abundances were associated with increased mortality and need for artificial ventilation.[19] Species potentially protective against SARS-CoV-2 infection include

Parabacteroides merdae, Bacteroides stercoris, Alistipes onderdonkii, Lachnospiracea bacterium[19] and *F. prausnitzii.*[19, 20], while vulnerability to infection and increased severity were associated with decreased abundance of *B. bifidum.*[20, 21] A recent study correlated aspects of the gut microbiome with "Long-COVID" including reduced levels of F. prausnitzii on admission[22]. In short, there is still a compelling need to elucidate changes in the human gut microbiome due to SARS-CoV-2 and their relationship with clinical outcomes.

The scientific community and lay public are increasingly interested in the therapeutic potential of probiotics. *Bifidobacteria* spp. have potential to improve clinical conditions ranging from inflammatory bowel disease (IBD)[23] to *Clostridioidies difficile* infections.[23, 24, 25, 26] Treatment with specific strains of *Bifidobacteria in vitro* have been shown to reduce toxins from *C. difficile* .[25] *In vivo*, *Bifidobacteria* can restore colonic integrity,[27] and *B. longum* administered intranasally in mice prior to exposure to influenza has been associated with reduction in mortality.[4] Given that *Bifidobacteria* are a common component of several probiotic products and appear to be associated with SAR-CoV-2 infections, one could ask if probiotics might have a role in SARS-CoV-2 therapy or prevention.

Herein, we evaluate the relationships between gut microbiome diversity and composition compared to clinical outcome in cross-sectional groups of SARS-CoV-2 PCR-confirmed positive patients (ranging from asymptomatic to severely symptomatic) versus SARS-CoV-2 PCR-confirmed negative controls. Our controls are SARS-CoV-2 exposed persons who remained PCR-negative and asymptomatic. The controls likely had similar viral exposures, but appeared protected against infection, and our data suggests some protection may reside in the microbiome.

METHODS

Study Design and Patients

Individuals who were tested for SARS-CoV-2 infection either because they were symptomatic or had been exposed to a "case" were eligible for enrollment the week following testing if either they or a household member was positive. Controls eligible for enrollment were PCR-negative for SARS-CoV-2, remained antibody negative for 3 to 6 months, and asymptomatic for 6 to 12 months. Additionally, controls had to either share a household with at least one symptomatic SARS-CoV-2-positive individual or be a healthcare worker who had been repeatedly exposed to symptomatic SARS-CoV-2-positive patients or numerous SARS-CoV-2 positive samples. All exposed controls were ones that, despite exposure to SARS-CoV-2, chose not to quarantine or take prophylaxis for SARS-CoV-2 infection and none had yet been vaccinated. Patients did not wear PPE inside their homes and staff did not wear *full* PPE (i.e., did not wear masks) at the office because of its scarcity during this global pandemic. Patients undergoing treatment with total parenteral nutrition, or those with a history of significant gastrointestinal surgery (e.g. bariatric surgery, total colectomy with ileorectal anastomosis, proctocolectomy, postoperative stoma, ostomy, or ileoanal pouch) were excluded.

This study was performed between March 1st, 2020 to October 31st, 2021, with all but one subject recruited prior to June 1st, 2021. During that time, alpha and epsilon variants predominated in the United States[28].

The study was conducted in accordance with ethical principles of the Declaration of Helsinki, the International Council for Harmonisation (ICH) Harmonised Tripartite Guideline for Good Clinical Practice (GCP), and the Ethical and Independent Review Board (IRB). All patients provided written informed consent to participate.

Assessments

A self-administered questionnaire solicited information on symptom severity, past medical history, current medication and probiotic use, and exposure to recreational drugs or animals. Patients with SARS-CoV-2 infection were further classified as being either asymptomatic carriers or having mild, moderate, or severe

symptoms as per National Institute of Health, Clinical Spectrum of SARS-CoV-2 Infection criteria.[29, 30] Asymptomatic PCR-confirmed SARS-CoV-2 positive household members of SARS-CoV-2 infected patients were categorized as asymptomatic carriers. Patients and controls were classified as underweight, normal weight, overweight, obese, or severely obese based on body mass index criteria of the Center for Disease Control and Prevention.[31]

Stool Sample Collection and Processing

Patients and controls within the same household collected stool samples within a week of the index case being positive. Patients had stool samples collected at baseline, prior to any treatment, and within 48 hrs. of symptom onset. No subjects had been commenced on antibiotics, SARS-CoV-2 infection treatments, OTC remedies (e.g. vitamins, antipyretics, analgesics), or supplemental oxygen between the time of symptom onset or demonstration of PCR positivity and stool collections. Subjects were instructed (and educated on the procedure and sterile methods) to collect 1 mL of fresh stool and place it directly in a DNA/RNA Shield™ Fecal Collection Tube (Zymo Research, Tustin, CA, USA), and then mix sample thoroughly. One ml of feces is more than sufficient to capture the microflora of the gut accurately and consistently. This method is chosen to eliminate the need for whole stool mixing and aliquoting. The solution in the Fecal Collection Tube is designed to preserve samples at ambient temperature (4°C-25°C) for > 2 years, or below -20°C indefinitely. Once samples reached our laboratory, they were immediately frozen at -20°C.

Following fecal collection, each individual sample DNA was extracted and purified with the Qiagen PowerFecal Pro DNA extraction kit. The isolated DNA was then quantitated utilizing the Quantus Fluorometer with the QuantFluor ONE dsDNA kit. After DNA quantification, the DNA was normalized, i.e. all samples begin library preparation (following DNA extraction and purification) with 100 ng input of DNA. Libraries were then prepared using shotgun methodology with Illumina's Nextera Flex kit. Samples then underwent the shotgun metagenomic processing procedure of tagmentation, amplification, indexing, and purification. Following completion of this shotgun metagenomic standard protocol, purified libraries

were again normalized to standardize sequencing depth during the NGS run on the NextSeq 500/550. We achieved consistency of sequencing depth (ie number of reads) by normalizing the samples' pooling concentrations (ie molarity), loading the same number of samples per sequencing run, consistently using the same NextSeq High Output kits.

After completion of sequencing on the Illumina NextSeq with 500/550 High-Output Kits v2.5 (300 cycles), the raw data was streamed in real-time to Illumina's BaseSpace cloud for FASTQ conversion. The FASTQ files were then sent through One Codex's bioinformatics pipeline for metagenomic annotation and analyses to elucidate the microflora composition and relative abundances of the top genera and species for all patients and controls.

Data Analysis

We assessed differences in relative abundance across taxa between the gut microbiome of SARS-CoV-2 infected patients and exposed controls and calculated Shannon and Simpson alpha diversity indices with One Codex's bioinformatics analysis pipeline utilizing Jupyter Notebook in Python. Specifically, the One Codex Database consists of ~114K complete microbial genomes (One Codex, San Francisco, CA, USA). During processing, reads were first screened against the human genome, then mapped to the microbial reference database using a k-mer based classification. Individual sequences (NGS read or contig) were compared against the One Codex Database (One Codex) by exact alignment using k-mers, where k = 31(43, 44). Based on the relative frequency, unique k-mers were filtered to control for sequencing or reference genome artifacts.

The sequencing depth followed ProgenaBiome's standard operating procedures and was 8,239,475 reads on average for this study. One should note that shallow metagenomic sequencing is typically only 0.5 million reads but is still considered sufficient for taxonomic phyla level analysis (and even genera for the most abundant bacteria).

The relative abundance of each microbial taxonomic classification was estimated based on the depth and coverage of sequencing across every available reference genome. Beta-diversity was calculated as weighted UniFrac distance visualized in a distance matrix using the phylum-level relative abundance obtained from One Codex. 13 genera were selected based on our experience and knowledge of critical players in the gut microbiome, as well as similarity to other studies [18, 20][29]

To compare patients across subgroups and patients to exposed controls, ANOVA, Mann-Whitney U, Kruskal-Wallis tests, and chi-square test statistics were conducted using GraphPad version 8 with P-values < 0.05 considered as significant. Dunn's *post-hoc* was used for Kruskal-Wallis test, with correction for multiple comparisons in all situations.

All authors had access to study data and reviewed and approved the final manuscript.

RESULTS

Patient Characteristics

Demographic and clinical characteristics of patients (n=50) and exposed controls (n=20) are presented in **Supplementary Table S1** and **Supplementary Table S2,** and summarized in **Table 1**. All patients were resident of USA, with states indicated in Supplementary Table 1. 24 of 50 (48%) of patients and 7 of 20 (35%) of exposed controls were male. The mean ± SEM age in years was 50.0 ± 2.5 for patients and 44.4 ± 3.6 for exposed controls. 44 of 50 (88%) of patients were Non-Hispanic White; 5 of 50 (10%), Hispanic; and 1 of 50 (2%), Native American and 17 of 20 (85.0%) of exposed controls were non-hispanic white; 2 of 20 (10.0%), Hispanic; and 1 of 20 (5.0%), Black. Of patients, 28 of 50 (56%) had severe, 12 of 50 (24%) had moderate and 6 of 50 (12%) had mild disease, and 4 of 50 (8%) were asymptomatic. 32 of 50 (64%) of patients and 12 of 20 (60.0%) of exposed controls had underlying comorbidities considered risk factors for increased severity of SARS-CoV-2 infection by the CDC.[1] The mean ± SEM BMI of the 46 patients with available data was 27.1 ± 0.98 compared with 25.1 ± 0.96 for the 20 exposed controls. There was no

significant difference (P>0.2) in gender, age, racial demographics, loss of appetite, change in stool frequency, diet, or presence of underlying comorbidities.

	SARS-CoV-2 Negative; Exposed control (n=20)	SARS-CoV-2 Positive					
		Asymptomatic (n=4)	Mild (n=6)	Moderate (n=12)	Severe (n=28)	Total (n=50)	P-value
Demographics							
USA Resident	20(100.00%)	4(100.00%)	6(100.00%)	12(100.00%)	28(100.00%)	50(100.00%)	ns
Male	7(35.00%)	3(75.00%)	2(33.33%)	5(41.66%)	14(50.00%)	24(48.00%)	0.5706
Mean Age ± SEM	44.40±3.62	47.50±9.40	37.67±4.65	50.58±5.92	52.82±3.33	50.00±2.50	0.5221
Median Age	48	50.5	37	60	55.5	53	
Race							
White	17(85.00%)	3(75.00%)	5(83.33%)	9(75.00%)	27(96.43%)	44(88.00%)	0.3826
Hispanic	2(10.00%)	1(25.00%)	0(0.00%)	3(25.00%)	1(3.57%)	5(10.00%)	
Black	1(5.00%)	0(0.00%)	0(0.00%)	0(0.00%)	0(0.00%)	0(0.00%)	
Other	0(0.00%)	0(0.00%)	1(16.66%)	0(0.00%)	0(0.00%)	1(2.00%)	
Clinical / dietary characteristics							
Severe COVID comorbidities*	12(60.00%)	3(75.00%)	3(50.00%)	10(83.33%)	16(57.14%)	32(64.00%)	0.5099
Normal stool frequency	20(100.00%)	4(100.00%)	6(100.00%)	10(83.33%)	24(85.71%)	44(88.00%)	0.2891
Lack of appetite	0(0.00%)	0(0.00%)	0(0.00%)	1(8.33%)	2(7.14%)	3(6.00%)	0.6663
Omnivore diet	19[&](100.00%)	4(100.00%)	6(100.00%)	12(100.00%)	28(100.00%)	50(100.00%)	ns

* Comorbid conditions indicative of severe SARS-CoV-2 infection (not including hypertension), based on CDC[32].
[&] 19 total subjects had data available for diet within exposed control.

Table 1: Summary of demographics along with clinical and dietary characteristics of subjects.

Numbers in cells indicate number of subjects with percentage in categories, except for age and BMI which indicate value. P-values calculated via one-way ANOVA (age and BMI) or chi-square (others). Normal stool frequency is defined as absence of diarrhea. Total refers to sum of SARS-CoV-2 positive subjects, and it is not used in statistics.

Of the exposed controls, 16 were household contacts of SARS-CoV-2 positive patients in the study, 2 were healthcare workers with extensive, non-protected, exposure to SARS-CoV-2 positive patients, and 2 were laboratory personnel exposed to thousands of SARS-CoV-2 samples (healthcare workers and laboratory personnel did not wear full PPE, i.e., did not wear a face mask, due its scarcity; see methods). During the timeframe of the study, none of the patients or controls were on SARS-CoV-2 prophylaxis or treatment, and none had yet been vaccinated. No patients or exposed control were positive for SARS-CoV-2 prior to the study.

Gut Microbiome Diversity and Composition

Figure 1 depicts pie charts of the composition of the gut microbiome for the exposed control at the phylum level (**Figure 1A**) and genus level (**Figure 1B**). At phylum level, Firmicutes and Bacteroides dominated, comprising 59.6% (exposed control) and 54.7% (SARS-Cov-2 positive) and 29.1% (Exposed control) and 40.4% (SARS-Cov-2 positive) of all phyla, repectively. At the level of genus, *Bacteroides* contributed 12.4% (exposed control) and 21.8% (SARS-Cov-2 positive), *Alistipes* 6.4% (Exposed control) and 7.2% (SARS-Cov-2 positive), and *Bifidobacteria* 7.6% (exposed control) and 1.5% (SARS-Cov-2 positive).

Figure 2 shows two diversity indices for all subgroups studied, namely Shannon Diversity (**Figure 2A**) and Simpson Diversity index (**Figure 2B**). The overall P value for Shannon index (richness of bacterial composition) demonstrated a significant (P=0.0499) decrease in diversity with increased severity, and significance was seen for exposed ctrl vs. severely symptomatic (P=0.0201), analyzed via. Kruskal-Wallis test. The Simpson (evenness of bacterial composition) indexes showed a trend (P=0.0581) of a decrease in diversity with increased SARS-CoV-2 severity.

Further metagenomic analysis comparing SARS-CoV-2 patients and controls revealed significant differences in relative abundance of specific bacteria. The relative abundance of SARS-COv-2 positive (exposed control) vs. negative subjects is presented in **Table 2**, along with comparative P-Values via. Mann-Whitney-U test. Patients with SARS-CoV-2 infection showed a significantly decreased relative abundance of *Bifidobacterium* and *Faecalibacterium*, and significantly increased relative abundance of *Bacteroides* (**Table 2**)

Table 2: Relative abundances of Bacteroides increase and of Bifidobacterium, Faecalibacterium, and Roseburium decrease in SARS-CoV-2 positive subjects vs. SARS-CoV-2 negative exposed controls. Mean $\pm$ SEM Relative abundances, as well as P-Value via Mann-Whitney-U test are indicated, with bold marking $P<0.05$.

Genus (+/- Species)	Relative Abundance (Mean ± SEM)		P-Value
	Exposed Controls	SARS-Cov-2 Positive	
Alistipes	0.0639±0.0095	0.0721±0.0100	0.8709
Bacteroides	0.1235±0.0178	0.2183±0.0191	**0.0025**
Bifidobacterium	0.0755±0.0219	0.0147±0.0051	**<0.0001**
Blautia	0.0261±0.0040	0.0524±0.0088	0.1349
Clostridium	0.0431±0.0075	0.0309±0.0039	0.9948
Collinsella	0.0146±0.0045	0.0158±0.0029	0.9948
Dorea	0.0137±0.0024	0.0185±0.0022	0.2777
Eubacterium	0.0441±0.0063	0.0402±0.0043	0.4786
Faecalibacterium	0.0550±0.0086	0.0310±0.0039	**0.0137**
F. prausnitzii	0.0542±0.0085	0.0313±0.0039	**0.0153**
Prevotella	0.0110±0.0086	0.0091±0.0066	0.6538
Roseburium	0.0329±0.0056	0.0195±0.0032	**0.0097**
Ruminococcus	0.0376±0.0079	0.0391±0.0056	0.9844

Table 3A lists the genera / species relative abundances (mean±SEM) for various levels of severity of SARS-CoV-2 positive patients vs. exposed control. Analyzed via Kruskal-Wallis test, the main effect (i.e. overall P-value) of these changes are shown in the left column. **Table 3B** proceeds to compare, correcting for multiple comparison, the three levels of severity in infected patients vs. exposed control and asymptomatic groups. Specifically, increased disease severity was associated with decreased relative abundance of *Bifidobacterium, Faecalibacterium, F. prausnitizii,* and *Roseburium,* along with an increased relative abundance of *Bacteroides*.

Depicted in **Figure 3** are the 12 most abundant families and the 12 most abundant genera for patients, stratified by disease severity and in comparison to exposed controls. Distinguished by

color, the bars represent the relative percent bacterial families and genera abundance. Note the reduced diversity of the microbiome of SARS-CoV-2 positive patients shown in column B.

Table 3: Relative abundance of Bacteroides increases and that of Bifidobacterium, Faecalibacterium and Roseburium decreases with increasing severity of disease. A. Relative abundance of genera/species for various severity of SARS-Cov-2 positivity, as well as exposed controls (SARS-CoV-2 negative). Overall P-value of Kruskal-Wallis test is indicated in 'Main Effect' column. B. P-value for various levels of severity of symptomatic infection, compared to negative Exposed Controls and positive asymptomatic subjects, using Dunn's *post-hoc*. For A and B, bold values indicate P<0.05. Note, no apparently significant (P<0.05) P-values were observed in *post-hocs*, with main effects non-significant.

A.

	Relative Abundance (mean ± SEM)					
Genus (+/-Species)	**Main Effect**	**Severe**	**Moderate**	**Mild**	**Asymptomatic**	**Exposed Control**
Alistipes	0.8119	0.0793± 0.0166	0.0520±0.0084	0.0664± 0.0196	0.0901±0.0272	0.0639± 0.0095
Bacteroides	**0.0075**	0.2187± 0.0272	0.2849±0.0305	0.0912± 0.0226	0.2058±0.0606	0.1235± 0.0178
Bifidobacterium	**<0.0001**	0.0018± 0.0006	0.0037±0.0015	0.0507± 0.0244	0.0840±0.0308	0.0755± 0.0219
Blautia	0.2098	0.0495± 0.0095	0.0426±0.0132	0.1037± 0.0510	0.0260±0.0067	0.0261± 0.0040
Clostridium	0.2721	0.0331± 0.0062	0.0334±0.0055	0.0265± 0.0083	0.0145±0.0025	0.0431± 0.0075
Collinsella	0.7476	0.0145± 0.0035	0.0107±0.0038	0.0203± 0.0126	0.0334±0.0174	0.0146± 0.0045
Dorea	0.4820	0.0218± 0.0035	0.0126±0.0032	0.0174± 0.0046	0.0152±0.0015	0.0137± 0.0024
Eubacterium	0.9619	0.0436± 0.0070	0.0367±0.0064	0.0366± 0.0085	0.0332±0.0058	0.0441± 0.0063
Faecalibacterium	**0.0077**	0.0209+ 0.0037	0.0428+0.0093	0.0359± 0.0139	0.0597+0.0098	0.0550± 0.0086

F. prausnitzii	**0.0054**	0.0220± 0.0041	0.0417±0.0092	0.0356± 0.0137	0.0589±0.0095	0.0542± 0.0085
Prevotella	0.1687	0.0149± 0.0118	0.0000±0.0000	0.0050± 0.0046	0.0023±0.0020	0.0110± 0.0086
Roseburium	**0.0327**	0.0146± 0.0037	0.0245±0.0075	0.0268± 0.0138	0.0274±0.0081	0.0329± 0.0056
Ruminococcus	0.8033	0.0384± 0.0076	0.0293±0.0073	0.0620± 0.0250	0.0394±0.0139	0.0376± 0.0079

B.

Genus (+/-Species)	**P-value vs. exposed control**				**P-value vs. asymptomatic**		
	Mild	**Moderate**	**Severe**	**Asymptomatic**	**Mild**	**Moderate**	**Severe**
Alistipes	>0.9999	>0.9999	>0.9999	>0.9999	>0.9999	>0.9999	>0.9999
Bacteroides	>0.9999	**0.0078**	>0.9999	>0.9999	>0.9999	>0.9999	>0.9999
Bifidobacterium	>0.9999	**0.0006**	**0.0026**	>0.9999	**>**0.9999	**0.0006**	**<0.0001**
Blautia	0.4116	>0.9999	0.6373	>0.9999	>0.9999	>0.9999	>0.9999
Clostridium	>0.9999	>0.9999	>0.9999	0.4944	>0.9999	0.9841	>0.9999
Collinsella	>0.9999	>0.9999	>0.9999	>0.9999	>0.9999	>0.9999	>0.9999
Dorea	>0.9999	>0.9999	>0.9999	>0.9999	>0.9999	>0.9999	>0.9999
Eubacterium	>0.9999	>0.9999	>0.9999	>0.9999	>0.9999	>0.9999	>0.9999
Faecalibacterium	>0.9999	>0.9999	**0.0082**	>0.9999	>0.9999	>0.9999	0.1422
F. prausnitzii	>0.9999	>0.9999	**0.0109**	>0.9999	>0.9999	>0.9999	0.1568
Prevotella	>0.9999	>0.9999	>0.9999	>0.9999	>0.9999	0.8916	>0.9999
Roseburium	>0.9999	>0.9999	**0.0196**	>0.9999	>0.9999	>0.9999	>0.9999
Ruminococcus	>0.9999	>0.9999	>0.9999	>0.9999	>0.9999	>0.9999	>0.9999

Figure 4 summarizes the microbiome changes according to SARS-CoV-2 positivity and severity, with green boxes depicting significant elevation and red boxes indicating significant depletion in genera / species abundance associated with SARS-CoV-2.

Figure 5A and **5B** exhibit the relative abundance of *Bifidobacterium* for each subject, grouped by SARS-CoV-2 infection severity. This diagram, with subjects groups ordered by severity (from

severe on left, to exposed controls on the right), depicts how Bifidobacterium abundance increases as severity decreases.

Analysis of the beta-diversity of subjects demonstrated that the diversity of control subjects cluster separately from that of patients. **Figure 6A** shows the beta-diversity weighted (quantitative) UniFrac analysis featuring phyla bacterial profiles for all individuals in the study (n=70)**. Figure 6A** reveals that, although there is a range of dissimilarity, the SARS-CoV-2 negative individuals are more similar to one another than they are to SARS-CoV-2 positive patients. The matrix also highlights clusters of similarity among SARS-CoV-2 positive patients, and darker quadrants of dissimilarity where positive and negative patients intersect. At a more granular level, **Figure 6B** utilized principal component (PC) analysis of genera where the axes depict the percent of variance. In PC analysis, points closer together are more similar (less divergence with axis representing directions of divergence). Herein the PC1 accounts for 43.16% of the variation, whereas PC2 accounts for 12.78%. This analysis reveals a clear divergence of a subset of SARS-CoV-2 positive patients clustering on the right side tracking along the x-axis (PC1), highlighting microbiota divergence as a function of disease. Thus, **Figure 6** shows that exposed controls cluster similar separately from SARS-CoV-2 patients; i.e. patients are more similar in terms of their microbiome to each other than to controls.

DISCUSSION

Immune function and health could be enhanced by bacterial abundance

Interactions between the host and gut microbiota are complex, numerous, and bidirectional. Gut microbiota regulate the development and function of the innate and adaptive immune systems,[33] potentially allowing them to protect against infections and infection severity. The primary findings of our study are that SARS-CoV-2 positivity and infection severity are associated with decreased

levels of the protective *Bifidobacterium* and *Faecalibacterium* genera and with decreased bacterial diversity, as exemplified by the Shannon and Simpson indices. This accords with studies showing bacterial diversity inversely relates to the presence of various common disorders.[34] Uniquely, our study compared SARS-CoV-2 exposed SARS-CoV-2 negative persons (i.e., controls) with symptomatic and asymptomatic SARS-CoV-2 positive patients. Thus, we controlled for SARS-CoV-2 exposure.

The genus *Bifidobacterium* has important immune functions,[8] is a major component of the microbiome and is frequently used in probiotics.[35] Bifidobacteria increase Treg responses and reduce cell damage by inhibiting TNF-α and macrophages.[36] Bifidobacteria also protect against intestinal epithelial cell damage independently from their effects on TNF-α production. The exopolysaccharide coat which is a feature of some *Bifidobacterium* plays a significant role in this protective effect.[37] These immune functions of *Bifidobacterium* could be critical in relation to its SARS-CoV-2 infection-prevention effects.

Evidence has accumulated to support a beneficial effect from supplementation with *Bifidobacterium* in numerous disease states.[38] The numbers of commensal Bifidobacteria have been shown to decrease with age and obesity, major SARS-CoV-2 infection risk factors. We demonstrate that patients with a more severe course of viral infection had decreased abundance of *Bifidobacterium*. However, it should be noted that there are no definitive studies concerning what constitutes a normal baseline abundance of *Bifidobacterium* in a “healthy” individual.

The abundance of *Faecalibacterium* genus and *F. prausnitzii* species were also inversely related to SARS-CoV-2 positivity and SARS-CoV-2 infection severity in this analysis. Age and diabetes are risk factors for SARS-CoV-2 infection, and *F. prausnitzii* levels decline markedly in elder and diabetic populations.[38] In fact, *Faecalibacterium* levels have been considered an indirect “indicator” of overall human health.[39] The abundance of *F. prausnitzii* is reduced by the

"Western" diet (consumption of more meat, animal fat, sugar, processed foods, and low fiber), while it is enhanced by the high-fiber containing "Mediterranean" diet of vegetables and fruits with low meat intake.[40] Preliminary studies showed that reduced ingestion of a Mediterranean diet within the same country is associated with increased SARS-CoV-2 related death rates.[41] In short, we show that *F. prausnitzii* levels negatively correlated to SARS-CoV-2 infection severity and prior studies show that reduced *F. prausnitzii* is associated with SARS-CoV-2 infection vulnerabilities such as age, diabetes, obesity, and possibly diet.

SARS-CoV-2 positivity and severity were also associated with decreased abundance of *Roseburium* and increased abundance of *Bacteroides.* The implications of these changes remain unclear.

Innate immunity could be enhanced by increased level of beneficial bacteria

The pathological impact of SARS-CoV-2 infection includes both direct effects from viral invasion and complex immunological responses including, in its most severe form, the 'cytokine storm.' The cytokine storm is the result of a sudden increase in circulating levels of pro-inflammatory cytokines produced by activated macrophages, mast cells, endothelial cells, and epithelial cells during innate immune responses, which appear to be modulated by the abundance of *Bifidobacteria* and *Faecalibacterium* and bacterial diversity(5, 23, 25) Steroid treatment has situational success in SARS-CoV-2 infection, based on suppressing this over activation of the innate immune system, reviewed by Tang et al.[42]

Zhao et al. reported that elevated serum levels of pro-inflammatory cytokines such as IL-16 and IL-17 predict poor prognoses in patients with SARS-CoV-2 infection.[43] Also, Tao et al. showed that changes in gut microbiota composition might contribute to SARS-CoV-2-induced production of inflammatory cytokines in the intestine, which may lead to cytokine storm onset.[29] Both authors report significantly reduced gut microbiota diversity and increased opportunistic pathogens in

SARS-CoV-2 patients. Interestingly, the bloom of opportunistic pathogens positively correlated with the number of Th17 cells. Bozkurt et al. reported that IL-6 and IL-17 promote viral persistence by immune interactions through cellular autophagy via the inositol-requiring enzyme 1 pathway.[16] Additionally, some species of *Bifidobacterium* are likely to prevent the replication of coronaviruses by reducing endoplasmic reticulum stress, also through the inositol-requiring enzyme 1 pathway. Reduced *Bifidobacterium* abundance has been observed in the gut microbiome of patients with IBD, which has mechanisms involving IL-17.[31] Furthermore, the direct endoscopic delivery of *Bifidobacterium* has been shown to be effective in promoting symptom resolution and mucosal healing in IBD—an effect likely to be associated with the anti-Th17 effect of *Bifidobacterium.*(8) **Figure 7** demonstrates how *Bifidobacteria* might hypothetically quell a heightened immune response by dampening the effect of the master switch TNF-α.

CONCLUSIONS

Given our cross-sectional study design, it is not possible to determine whether the differences in *Bifidobacterium* levels observed between patients and exposed controls preceded or followed infection. If preceding infection, they could be a marker of susceptibility and boosting *Bifidobacterium* levels might decrease the risk or severity of SARS-CoV-2 infection. If these changes followed infection, alteration of the gut microbiome (such as through fecal microbiota transplantation or possibly probiotic supplementation) to increase *Bifidobacterium spp.* could be an area worth exploring for improved outcomes. If future studies can demonstrate improved outcomes, such therapy can be considered for complex cases of SARS-CoV-2 infection, such as "long-haulers," and those with severe disease. Developing outbreaks within tightly closed communities such as nursing homes might be a good setting in which to assess susceptibility: fecal samples could be collected during the outbreak and run *post hoc* on "cases" and "controls." Future studies of

individuals with baseline pre-pandemic microbiome data would be highly valuable, although acquiring such baseline pre-infection microbiome data is still costly.

With the lack of data on the gut microbiome prior to onset of SARS-CoV-2 infection, we cannot completely rule out the confounding effect of illness on the microbiome. Nonetheless, we eliminated effects of treatment on the gut microbiome by sampling prior to administration of SARS-CoV-2 infection therapeutics of any kind and within 48 hrs. of symptom onset. Specifically, no subjects were given antibiotics, antivirals, anti-inflammatory medicines, oxygen, or any other therapeutic agent between symptom onset or PCR positivity, and stool sampling. We also note that the prevalence of appetite changes, alterations of stool frequency, and GI symptoms, in general, were not significantly different between any of the severity groups or controls (Table 1), although the small sample sizes for some groups should be considered in evaluating these statistics.

SARS-CoV-2 infection presentation variability correlates with colon microbiome bacterial composition and overall diversity. The same changes we observe due to SARS-CoV-2 infection, namely reduced *Bifidobacterium* and/or *Faecalibacterium* abundance, are associated with SARS-CoV-2 infection risk factors including old age, obesity, and diabetes.[9, 38, 40, 44] Thus, colon microbiome diversity and relative abundance of *Bifidobacterium and Faecalibacterium* should be explored as potential markers for predicting SARS-CoV-2 infection severity.

In summary, we demonstrate in a study of PCR-positive and PCR-negative SARS-CoV-2-exposed subjects, reduced bacterial diversity and reduced levels of various genus / species are highly associated with both SARS-CoV-2 positivity and SARS-CoV-2 infection severity. These findings suggest that probiotic supplementation or fecal microbiota transplantation should be explored as a potential therapeutic avenue, for SARS-CoV-2 patients. Additionally, individual colon microbiome evaluation may predict vulnerability to the development of severe SARS-CoV-2 infection. Lastly, our data suggest a new area for exploration: if SARS-CoV-2 severity is found to be dependent on

the microbiome, then accounting for microbiome differences could reduce variability in outcomes for SARS-CoV-2.

ABBREVIATIONS:

CDC (Center for Disease Control); GCP (good clinical practice); IBD (inflammatory bowel disease); ICH (International Council for Harmonisation); IL (interleukin); IRB (Independent Review Board); NGS (next generation sequencing); NIH (National Institute of Health); PC (Principal Component); PCR (polymerase chain reaction); PPE (personal protective equipment); SARS-CoV-2 (Coronavirus, COVID, COVID-19); TNF (tumour necrosis factor)

DECLARATIONS

Ethics approval and consent to participate: The study was conducted in accordance with ethical principles of the Declaration of Helsinki, the International Council for Harmonisation (ICH) Harmonised Tripartite Guideline for Good Clinical Practice (GCP), and the Ethical and Independent Review Board (IRB, #IRB00007807). All patients provided written informed consent to participate.

Availability of data and materials: The datasets used and analyzed during the current study

are available from the corresponding author on reasonable request.

Competing interests: SH declares that she has pecuniary interest in Topelia Pty Ltd in Australia, and Topelia Pty Ltd in USA where development of COVID-19 preventative/treatment options are being pursued. She has also filed patents relevant to Coronavirus treatments. She is the Founder and owner of Microbiome research foundation, Progenabiome and Ventura Clinical Trials.

TJB declares that he has pecuniary interest in Topelia Pty Ltd in Australia, and Topelia Therapeutics Inc. in USA developing COVID-19 preventative/treatment medications. He has also filed patents relevant to COVID-19 treatments.

SD declares she has corporate affiliation to McKesson Specialty Health / Ontada and North End Advisory, LLC. SD is unaware of SARS-CoV-2 and microbiome projects and not directly involved in COVID-19 relevant projects at McKesson, but they may exist. AJP and BDB have corporate affiliations to Progenabiome. EMMQ serves as a consultant to Precisionbiotics, Novazymes, Salix, Biocodex and Axon Pharma and has received research support from 4D Pharma.

Funding: No funding was received for this manuscript. Several authors were compensated or salaried by ProgenaBiome.

Authors' contributions: All authors (SH, NS, HB, SD, AJP, JD, BDB, EMMQ, and TJB) participated in the drafting, critical revision, and approval of the final version of the manuscript. SH led study design. SH and AJP conducted the bioinformatic analysis. SD conducted the statistical analysis and was a major contributor to writing the paper. SH was primarily responsible for interpretation of the study results, with contributions from all authors. EMMQ and TJB are senior authors who provided overall direction and advice.

Acknowledgements: Medical writing assistance was provided by Sonya Dave, PhD (an author on the publication) and was funded by ProgenaBiome. The authors thank all clinicians for their involvement and contribution to the study. The authors thank Kate Hendricks, MD, MPH&TM for many helpful editorial suggestions. Finally, the authors owe a depth of gratitude to the late Sydney M Finegold, MD for mentorship that sparked the interest in the microbiome to many scientists, including authors of this paper.

REFERENCES

1 De Vuyst L, Moens F, Selak M, Riviere A, Leroy F. Summer Meeting 2013: growth and physiology of bifidobacteria. J Appl Microbiol 2014;**116**:477-91.

2 Parameswaran N, Patial S. Tumor necrosis factor-alpha signaling in macrophages. Crit Rev Eukaryot Gene Expr 2010;**20**:87-103.

3 Martins AKS, Martins FS, Gomes DA, Elian SDA, Vieira AT, Teixeira MM*, et al.* Evaluation of in vitro antagonism and of in vivo immune modulation and protection against pathogenic experimental challenge of two probiotic strains of Bifidobacterium animalis var. lactis. Arch Microbiol 2010;**192**:995-1003.

4 Groeger D, Schiavi E, Grant R, Kurnik-Lucka M, Michalovich D, Williamson R*, et al.* Intranasal Bifidobacterium longum protects against viral-induced lung inflammation and injury in a murine model of lethal influenza infection. EBioMedicine 2020;**60**:102981.

5 Konieczna P, Akdis CA, Quigley EM, Shanahan F, O'Mahony L. Portrait of an immunoregulatory Bifidobacterium. Gut Microbes 2012;**3**:261-6.

6 Konieczna P, Ferstl R, Ziegler M, Frei R, Nehrbass D, Lauener RP*, et al.* Immunomodulation by Bifidobacterium infantis 35624 in the murine lamina propria requires retinoic acid-dependent and independent mechanisms. PLoS One 2013;**8**:e62617.

7 Schiavi E, Plattner S, Rodriguez-Perez N, Barcik W, Frei R, Ferstl R*, et al.* Exopolysaccharide from Bifidobacterium longum subsp. longum 35624 modulates murine allergic airway responses. Benef Microbes 2018;**9**:761-73.

8 Ruiz L, Delgado S, Ruas-Madiedo P, Sánchez B, Margolles A. Bifidobacteria and their molecular communication with the immune system. Front Microbiol 2017;**8**:2345-.

9 Marras L, Caputo M, Bisicchia S, Soato M, Bertolino G, Vaccaro S*, et al.* The Role of Bifidobacteria in Predictive and Preventive Medicine: A Focus on Eczema and Hypercholesterolemia. Microorganisms 2021;**9**.

10 Stavropoulou E, Bezirtzoglou E. Probiotics in medicine: A long debate. Front Immunol 2020;**11**:2192-.

11 Ahlawat S, Asha, Sharma KK. Immunological co-ordination between gut and lungs in SARS-CoV-2 infection. Virus Res 2020;**286**:198103-.

12 Follmer C. Viral infection-induced gut dysbiosis, neuroinflammation, and α-synuclein aggregation: Updates and perspectives on COVID-19 and neurodegenerative disorders. ACS chemical neuroscience 2020;**11**:4012-6.

13 Marsland BJ, Trompette A, Gollwitzer ES. The Gut-Lung Axis in Respiratory Disease. Ann Am Thorac Soc 2015;**12 Suppl 2**:S150-6.

14 Janda L, Mihalcin M, Stastna M. Is a healthy microbiome responsible for lower mortality in COVID-19? Biologia (Bratisl) 2020:1-11.

15 Tiwari SK, Dicks LMT, Popov IV, Karaseva A, Ermakov AM, Suvorov A*, et al.* Probiotics at War Against Viruses: What Is Missing From the Picture? Front Microbiol 2020;**11**:1877.

16 Bozkurt HS, Quigley EM. The probiotic Bifidobacterium in the management of Coronavirus: A theoretical basis. Int J Immunopathol Pharmacol 2020;**34**:2058738420961304.

17 Jin X, Lian JS, Hu JH, Gao J, Zheng L, Zhang YM*, et al.* Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut 2020;**69**:1002-9.

18 Gu S, Chen Y, Wu Z, Chen Y, Gao H, Lv L*, et al.* Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza. Clin Infect Dis 2020;**71**:2669-78.

19 Zuo T, Liu Q, Zhang F, Lui GC, Tso EY, Yeoh YK*, et al.* Depicting SARS-CoV-2 faecal viral activity in association with gut microbiota composition in patients with COVID-19. Gut 2021;**70**:276-84.

20 Yeoh YK, Zuo T, Lui GC, Zhang F, Liu Q, Li AY, *et al.* Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut 2021;**70**:698-706.

21 Xu K, Cai H, Shen Y, Ni Q, Chen Y, Hu S, *et al.* [Management of COVID-19: the Zhejiang experience]. Zhejiang Da Xue Xue Bao Yi Xue Ban 2020;**49**:147-57.

22 Liu Q, Mak JWY, Su Q, Yeoh YK, Lui GC, Ng SSS, *et al.* Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut 2022.

23 Din AU, Hassan A, Zhu Y, Zhang K, Wang Y, Li T, *et al.* Inhibitory effect of Bifidobacterium bifidum ATCC 29521 on colitis and its mechanism. J Nutr Biochem 2020;**79**:108353.

24 Nitzan O, Elias M, Peretz A, Saliba W. Role of antibiotics for treatment of inflammatory bowel disease. World J Gastroenterol 2016;**22**:1078-87.

25 Valdes-Varela L, Hernandez-Barranco AM, Ruas-Madiedo P, Gueimonde M. Effect of Bifidobacterium upon Clostridium difficile Growth and Toxicity When Co-cultured in Different Prebiotic Substrates. Front Microbiol 2016;**7**:738.

26 Wei Y, Yang F, Wu Q, Gao J, Liu W, Liu C, *et al.* Protective effects of Bifidobacterial strains against toxigenic Clostridium difficile. Front Microbiol 2018;**9**:888-.

27 Philippe D, Heupel E, Blum-Sperisen S, Riedel CU. Treatment with Bifidobacterium bifidum 17 partially protects mice from Th1-driven inflammation in a chemically induced model of colitis. Int J Food Microbiol 2011;**149**:45-9.

28 Overview of Variants in Countries. https://covariants.org/per-country

29 Tao W, Zhang G, Wang X, Guo M, Zeng W, Xu Z, *et al.* Analysis of the intestinal microbiota in COVID-19 patients and its correlation with the inflammatory factor IL-18. Med Microecol 2020;**5**:100023.

30 Yagisawa M FP, Hanaki H, Ōmura S. . Global trends in clinical studies of ivermectin in COVID-19. Japanese Journal of Antibiotics 2021;**74**:44-94.

31 Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology 2014;**146**:1489-99.

32 Center for Disease Control. People with Certain Medical Conditions. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html 33 Negi S, Das DK, Pahari S, Nadeem S, Agrewala JN. Potential role of gut microbiota in induction and regulation of innate immune memory. Front Immunol 2019;**10**.

34 Lloyd-Price J, Abu-Ali G, Huttenhower C. The healthy human microbiome. Genome Med 2016;**8**:51.

35 Ghouri YA, Richards DM, Rahimi EF, Krill JT, Jelinek KA, DuPont AW. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol 2014;**7**:473-87.

36 Hughes KR, Harnisch LC, Alcon-Giner C, Mitra S, Wright CJ, Ketskemety J*, et al.* Bifidobacterium breve reduces apoptotic epithelial cell shedding in an exopolysaccharide and MyD88-dependent manner. Open Biol 2017;**7**.

37 Fanning S, Hall LJ, Cronin M, Zomer A, MacSharry J, Goulding D*, et al.* Bifidobacterial surface-exopolysaccharide facilitates commensal-host interaction through immune modulation and pathogen protection. Proc Natl Acad Sci U S A 2012;**109**:2108-13.

38 Arboleya S, Watkins C, Stanton C, Ross RP. Gut Bifidobacteria Populations in Human Health and Aging. Front Microbiol 2016;**7**:1204.

39 Ferreira-Halder CV, Faria AVS, Andrade SS. Action and function of Faecalibacterium prausnitzii in health and disease. Best Pract Res Clin Gastroenterol 2017;**31**:643-8.

40 Ganesan K, Chung SK, Vanamala J, Xu B. Causal Relationship between Diet-Induced Gut Microbiota Changes and Diabetes: A Novel Strategy to Transplant Faecalibacterium prausnitzii in Preventing Diabetes. Int J Mol Sci 2018;**19**.

41 Greene MW, Roberts AP, Fruge AD. Negative Association Between Mediterranean Diet Adherence and COVID-19 Cases and Related Deaths in Spain and 23 OECD Countries: An Ecological Study. Front Nutr 2021;**8**:591964.

42 Tang L, Yin Z, Hu Y, Mei H. Controlling Cytokine Storm Is Vital in COVID-19. Front Immunol 2020;**11**:570993.

43 Zhao M. Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies. Int J Antimicrob Agents 2020;**55**:105982.

44 Biagi E, Nylund L, Candela M, Ostan R, Bucci L, Pini E*, et al.* Through ageing, and beyond: gut microbiota and inflammatory status in seniors and centenarians. PLoS One 2010;**5**:e10667.



Figure 1: Distribution of bacterial relative abundance in various A. phlya and B. genera for exposed control (n=20, left) and SARS-CoV-2 positive subjects (n=50, right).



Figure 2: Diversity of gut microbiome composition of SARS-CoV-2 positive patients (Severely symptomatic: n=28; Moderately Symptomatic: n=12; Mildly Symptomatic: n = 6; Asymptomatic: n=4) vs. exposed controls (n=20). A. Shannon index (P=0.0499) B. Simpson index (P=0.0581). Differences between severely symptomatic positive and exposed negative controls were analyzed via. Kruskal-Wallis test Dunn's post-hoc, correcting for multiple comparisons, showing significant for Shannon index at P=0.0201.



Figure Figure 3: Graphic of relative abundance of the 12 most common A. families and B. genera.

The top group represents the SARS-CoV-2 positive samples (n=50), stratified by severity. The bottom group represents the exposed control samples (n=20). The colored boxes represent the fraction of the entire rectangle composed of the given family/genera of bacteria.



Figure 4: Diagram of taxa comparing the gut microbiome of SARS-CoV-2 patients and exposed controls.

Red or green background indicates a significant depletion or increase (due to positivity or severity), respectively, of the genus or species in SARS-CoV-2 positive subjects.

A.



B.



Figure 5: Relative abundance of *Bifidobacteria* in SARS-CoV-2 positive patients (n=50) vs. SARS-CoV-2 negative exposed controls (n=20). Data is plotted as A. mean with error bars for 95% CI and B. individual points of relative abundance for varying SARS-CoV-2 infection severity. Analyzed via Kruskal-Wallis test, there were significant reductions in *Bifidobacteria* relative

abundance for severely (P<0.0001) and moderately (P=0.0002) symptomatic patients. Subjects 1-28 = severely symptomatic; subjects 29-40 = moderately symptomatic; subjects 41-46 = mildly symptomatic subjects; subjects 47-50 = asymptomatic; subjects 51 – 70 = exposed control. Note: Figure A and B depict same data.

A.



B.



Figure 6: SARS-CoV-2 positive patients microbiome is more similar to each other than to that of exposed controls. A. Weighted UniFrac distance matrix of phylum level SARS-CoV-2 positive (n=50) and exposed negative control samples (n=20). Distance of microbiome differences increases with increasing blue color intensity (see legend top right). The center of the diagram consists of negative subjects on both axis, and is yellow indicative of less distance (i.e. less difference in microbiome). The central area of the left as well as central-top side of diagram, consists of negative subjects on one axis and positive on the other, and are darker blue, indicative of more distance (more difference in microbiome). B. Principal component analysis of microbiota from SARS-CoV-2 positive (n=50) and exposed negative controls (n=20). Dots closer in distance are more similar in microbiome composition. Axes depict the percent of variance explained by principal component (PC) 1 and 2. Plots are based on bacterial genera relative abundance profiles.



Figure 7: Potential mechanism for cytokine storm and immune hyper-response in SARS-CoV-2 positive patients.

In individuals infected with SARS-CoV-2, the macrophages become activated; these in turn activate T-cells, additional macrophages, and neutrophils—all of which release cytokines, including TNF-α. *Bifidobacteria*, when present in sufficient numbers, can bind to TNF-α and prevent the subsequent cytokine storm. Therefore, patients with a bifidobacterial dysbiosis characterized by low levels of *Bifidobacteria* lack this line of defence, which may lead to a cytokine storm.

Table 1. Demographic and baseline clinical characteristics of SARS-CoV-2-positive patients and SARS-CoV-2-negative exposed controls

Ranges: 1-5, 6-10, 11-15, 16-20, 21-25

No	Age	Sex	Ethnicity+	Risk Factors	BMI*	PCR Result	Category
1	21-25	F	NHW	none	24.8	positive	severe
2	71-75	M	H	none	18.4	positive	severe
3	86-90	M	NHW	Alzheimer's	21.1	positive	severe
4	16-20	F	NHW	none	22.0	positive	severe
5	31-35	M	NHW	overweight	26.9	positive	severe
6	41-45	F	NHW	overweight	25.8	positive	severe
7	66-70	F	NHW	overweight	25.8	positive	severe
8	56-60	M	NHW	overweight	27.3	positive	severe
9	41-45	F	NHW	overweight	27.8	positive	severe
10	51-55	M	NHW	obesity	30.7	positive	severe
11	36-40	M	NHW	hypertension	23.8	positive	mild
12	56-60	M	NHW	none	22.7	positive	severe
13	66-70	F	NHW	hypertension	22.9	positive	severe
14	55-60	M	NHW	obesity, HIV	37.2	positive	severe

15	66-70	F	NHW	hypertension, diabetes mellitus, obesity, cerebral aneurysm	48.5	positive	severe
16	66-70	M	NHW	hypertension, obesity, pulmonary embolus	33.2	positive	severe
17	46-50	F	NHW	overweight	27.4	positive	severe
18	56-60	M	NHW	hypertension, overweight	26.2	positive	severe
19	61-65	F	NHW	hypertension, overweight	28.1	positive	severe
20	56-60	F	NHW	hypertension	NA	positive	severe
21	51-55	F	NHW	none	24.5	positive	severe
22	36-40	M	NHW	obesity	30.7	positive	severe
23	6-10	M	NHW	none	14.5	positive	severe
24	51-55	M	NHW	none	24.1	positive	severe
25	51-55	F	NHW	hypertension, overweight	25.0	positive	severe
26	61-65	F	NHW	none	23.8	positive	severe
27	71-75	F	NHW	none	19.5	positive	severe

28	61-65	M	NHW	obesity, hypertension	31.5	positive	severe
29	21-25	F	NHW	obesity	30.9	positive	moderate
30	21-25	F	NHW	obesity, asthma	30.6	positive	moderate
31	21-25	F	NHW	asthma	NA	positive	moderate
32	36-40	F	H	hypertension, overweight	25.4	positive	moderate
33	31-35	M	H	none	18.4	positive	moderate
34	61-65	F	H	overweight	NA	positive	moderate
35	61-65	M	NHW	COPD	NA	positive	moderate
36	71-75	M	NHW	hypertension, severe obesity	48.5	positive	moderate
37	66-70	M	NHW	obesity	33.1	positive	moderate
38	66-70	M	NHW	obesity	30.7	positive	moderate
39	56-60	F	NHW	obesity	32.0	positive	moderate
40	66-70	F	NHW	hypertension	20.9	positive	moderate
41	16-20	M	NHW	none	23.5	positive	mild
42	36-40	F	NHW	none	18.6	positive	mild
43	31-35	F	NHW	overweight	28.5	positive	mild

44	51-55	M	NHW	overweight	29.0	positive	mild
45	36-40	F	--	obesity	31.3	positive	mild
46	41-45	F	NHW	hypertension	23.0	positive	mild
47	21-25	M	NHW	overweight	25.8	positive	asymptomatic
48	46-50	F	H	none	20.4	positive	asymptomatic
49	66-70	M	NHW	overweight	28.5	positive	asymptomatic
50	51-55	M	NHW	obesity, diabetes	35.3	positive	asymptomatic
51	66-70	F	NHW	overweight, + relative	26.6	negative	exposed
52	56-60	F	H	obesity, + relative	30.0	negative	exposed
53	51-55	F	NHW	hypertension, prediabetes, + relatives	25.0	negative	exposed
54	61-65	M	NHW	overweight, + relative	26.4	negative	exposed
55	26-30	M	NHW	overweight, + relative	26.4	negative	exposed

56	21-25	F	NHW	overweight, + relative	26.4	negative	exposed
57	61-65	F	NHW	none, (kissed) + boyfriend	17.4	negative	exposed
58	51-55	F	NHW	none, + relatives	19.9	negative	exposed
59	16-20	F	NHW	none, + relative	21.2	negative	exposed
60	26-30	M	--	none, + patients	19.5	negative	exposed
61	56-60	F	--	none, + patient samples	25.5	negative	exposed
62	51-55	F	--	none, + workers, + patients, + patient samples	24.0	negative	exposed
63	31-35	M	NHW	none, + relative	23.7	negative	exposed
64	31-35	M	NHW	none, +	21.7	negative	exposed

				roommate			
65	61-65	F	H	prediabetic, overweight, + physician, + relative	26.0	negative	exposed
66	41-45	F	--	overweight, + patient samples	26.6	negative	exposed
67	41-45	F	--	obesity, + patients	35.1	negative	exposed
68	41-45	M	--	overweight, + patients, + patient samples	27.2	negative	exposed
69	51-55	M	--	overweight, + patients	27.1	negative	exposed
70	11-15	F	NHW	overweight, + relative	27.1	negative	exposed

BMI, body mass index; [+] NHW = non-Hispanic White, H = Hispanic, B=Black, NA = Native American; Note: some ethnicities removed to maintain confidentiality

Supplementary Table S2: Detailed SARS-CoV-2 clinical characteristics and typical dietary habits of subjects.

No.	Severity	GI Symptoms	Loss of appetite?	SARS-CoV-2 Symptoms	Diet
1	severe	None	N	Fever, cough , hypoxemia 88%, anosmia	Omnivore
2	severe	None	Y	Fever, cough, hypoxemia of 92%, anosmia, anorexia	Mexican diet, omnivore
3	severe	None	N	Fever, cough, hypoxemia of 88%, anosmia	Omnivore
4	severe	None	N	Fever, Tourette's-like symptoms, anosmia	Omnivore
5	severe	Diarrhea	N	Fever, cough, no anorexia, anosmia, hematochezia, dizziness, hypoxemia 92%	Omnivore
6	severe	None	N	Fever, cough, anosmia, hypoxemia 91%	Omnivore
7	severe	None	N	Fever, cough, anosmia	Omnivore
8	severe	Diarrhea, abdominal pain	N	Pain while eating, dehydration, fever, anosmia, cough, short of breath, hypoxemia 88%	Omnivore
9	severe	None	N	Fever, cough, short of breath, anosmia, dizziness, anosmia, hypoxemia 89%, neurological symptoms	Omnivore
10	severe	None	N	Fever, cough, hypoxemia 88%, anosmia	Omnivore
11	severe	Diarrhea	N	Fever, headache, chills, body pain	Omnivore
12	severe	Heartburn	N	Fever, cough, short of breath, hypoxemia	Omnivore

				88%, Anosmia	
13	severe	Heartburn	N	Fever, cough, hypoxemia 88%, anosmia, full body rash	Omnivore
14	severe	None	Y	Fever, chills, chest pain, short of breath, hypoxemia 94%, anorexia, anosmia	Omnivore
15	severe	None	N	Cough, fever, short of breath, hypoxemia 88%, rash	Omnivore
16	severe	None	N	Cough, fever, short of breath, hypoxemia 88%	Omnivore
17	severe	None	N	Fever, cough, hypoxemia of 89-90%, anosmia	Omnivore
18	severe	None	N	Fever, cough, hypoxemia 88%, anosmia	Omnivore
19	severe	None	N	Fever, cough, hypoxemia 88%, anosmia, chest pain	Omnivore
20	severe	Diarrhea	N	Fever, cough, hypoxemia 88%, anosmia	Omnivore
21	severe	None	N	Fever, cough, anosmia, oxygen saturation not recorded, short of breath	Omnivore
22	severe	None	N	Fever, cough, anosmia, short of breath	Omnivore
23	severe	None	N	Anosmia, high fever, cough, short of breath, hypoxemia 93%	Omnivore
24	severe	None	N	Anosmia, high fever, cough, short of breath, hypoxemia 90%	Omnivore
25	severe	None	N	Anosmia, high fever, cough, short of breath, hypoxemia 90%	Omnivore
26	severe	None	N	Cough, anosmia, short of breath,	Omnivore

				headache, sinus issues, oxygen saturation not recorded	
27	severe	None	N	Anosmia, high fever, cough, short of breath, hypoxemia 92%-93%	Omnivore
28	Severe	None	N	Anorexia, anosmia, cough, fever, short of breath, dizziness, sore throat, fatigue, hypoxemia 91%	Omnivore
29	moderate	Diarrhea	N	Cough, fever, short of breath, oxygen saturation 98%, went to ER not admitted	Omnivore
30	moderate		N	Cough, anosmia, oxygen saturation 100%, fever	Omnivore
31	moderate	Diarrhea	N	Cold symptoms, sinusitis, rhinorrhea, fever, cough, anosmia, stable oxygen saturation	Omnivore
32	moderate	None	N	Chest pain, fever, severe headaches/migraines, body aches, chest pressure, anosmia, oxygen saturation 100%	Mexican diet, omnivore
33	moderate	Nausea	N	Rhinorrhea, congestion, body ache, fever of 101°, anosmia, oxygen saturation 99%	Mexican diet, omnivore
34	moderate	None	N	Anosmia, anorexia, fatigue, cough, oxygen saturation 98%	Omnivore
35	moderate	Abdominal pain	N	Chest tightness, headache, head congestion, cough, oxygen saturation 100%	Omnivore

36	moderate	None	N	Sluggish, cough, nasal congestion, oxygen saturation 98%	Omnivore
37	moderate	None	N	Myalgia, backache, oxygen saturation 99%	Omnivore
38	moderate	None	N	Fever, cough, anosmia, oxygen saturation 95%	Omnivore
39	moderate	None	N	rhinorrhea, anosmia, mild cough oxygen saturation 98%	Omnivore
40	moderate	None	N	Cough, headache, oxygen saturation 96%	Omnivore
41	mild	None	N	Nasal congestion, oxygen saturation 100%	Omnivore
42	mild	Bloating	N	Fever, cough, anosmia, rhinorrhea, oxygen saturation 100%	Omnivore
43	mild	None	N	Congestion, sinusitis, anosmia, oxygen saturation 100%	Omnivore
44	mild	None	N	Fatigue, short of breath, anosmia, oxygen saturation 100%	Omnivore
45	mild	None	N	Cough, fatigue, dizziness, sore throat, myalgia, oxygen saturation 100%	Omnivore
46	mild	None	N	Cough, head congestion, oxygen saturation 98%	Omnivore
47	asymptomatic	None	N	None	Omnivore
48	asymptomatic	None	N	None	Mexican diet, omnivore
49	asymptomatic	None	N	None	Omnivore

50	asymptomatic	None	N	None	Armenian diet, omnivore
51	Ctrl	None	N	None	Omnivore
52	Ctrl	None	N	None	Omnivore
53	Ctrl	None	N	None	Omnivore
54	Ctrl	None	N	None	Kosher, omnivore
55	Ctrl	None	N	None	Kosher, omnivore
56	Ctrl	None	N	None	Kosher, omnivore
57	Ctrl	None	N	None	Omnivore
58	Ctrl	None	N	None	Kosher, omnivore
59	Ctrl	None	N	None	Kosher, omnivore
60	Ctrl	None	N	None	Omnivore
61	Ctrl	None	N	None	Omnivore
62	Ctrl	None	N	None	Omnivore
63	Ctrl	None	N	None	Omnivore
64	Ctrl	None	N	None	Omnivore
65	Ctrl	None	N	None	Omnivore
66	Ctrl	None	N	None	Omnivore
67	Ctrl	None	N	None	Omnivore
68	Ctrl	None	N	None	Omnivore

69	Ctrl	None	N	None	Kosher, omnivore
70	Ctrl	None	N	None	Not available